Aprea Therapeutics Stock Statistic Functions Variance
| APRE Stock | USD 0.74 -0.03 -3.90% |
| Symbol |
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. Aprea Therapeutics Variance is a measurement of the price spread between periods of Aprea Therapeutics price series.
Aprea Therapeutics Technical Analysis Modules
Most technical analysis of Aprea Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Aprea from various momentum indicators to cycle indicators. When you analyze Aprea charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The companys products pipeline also includes ATRN-Backup, an ATR inhibitor ATRN-W1051 to treat anti-tumor activity and ATRN-DDRi. Aprea Therapeutics is traded on NASDAQ Exchange in the United States. As a micro-cap equity, Aprea Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 0.8. Aprea Therapeutics has a market cap of 8.43 M, ROE of -74.72%.
Methodology
Unless otherwise specified, financial data for Aprea Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Aprea (USA Stocks:APRE) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Aprea Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Aprea Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardLearn to be your own money manager
Tracking Aprea Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Watchlist Optimization Now
Watchlist OptimizationOptimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
| All Next | Launch Module |
Aprea Therapeutics pair trading
Pair trading with Aprea Therapeutics can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Aprea Therapeutics Pair Trading
Aprea Therapeutics Pair Trading Analysis
Identifying correlated replacements for Aprea Therapeutics is particularly important in concentrated portfolios where Aprea Therapeutics represents a large allocation. A poor substitute could introduce unintended factor or sector risks that persist beyond the required waiting period.
Correlation is not causation, but for Aprea Therapeutics it is a practical tool. High correlations between Aprea Therapeutics and a potential addition to the portfolio flag concentrated exposure, while low correlations signal diversification potential.
Correlation analysis and pair evaluation for Aprea Therapeutics can support hedging context. The method can be applied across sectors and broader equity sets.More Resources for Aprea Stock Analysis
Reviewing Aprea Therapeutics commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Aprea Stock:Aprea Therapeutics has a market cap of 8.43 M, ROE of -74.72%. See Trending Equities for portfolio-level analysis. This suggests a position in Aprea Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Our How to Buy Aprea Stock guide explains the steps to invest in Aprea Therapeutics stock.Analysis related to Aprea Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Earnings Share -2.12 | Revenue Per Share | Quarterly Revenue Growth -0.99 | Return On Assets | Return On Equity |
Investors evaluate Aprea Therapeutics using market value and book value, each describing different facets of the business. Aprea Therapeutics' market capitalization is 8.43 M. A P/B ratio of 0.8 suggests Aprea Therapeutics trades near or below book value. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Aprea Therapeutics differs from its quoted price, since each reflects a different lens. For Aprea Therapeutics, key inputs include a P/B ratio of 0.8, ROE of -74.72%, and revenue of 1.5 M. Trading price represents the transaction level agreed by market participants.